Prevalence of germline mutations in genes engaged in DNA damage repair by homologous recombination in patients with triple-negative and hereditary non-triple-negative breast cancers

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Domagala, Pawel ^a   Jakubowska, Anna ^a   Jaworska Bieniek, Katarzyna ^a   Kaczmarek, Katarzyna ^a   Durda, Katarzyna ^a   Kurlapska, Agnieszka ^a   Cybulski, Cezary ^a   Lubinski, Jan ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; ATM GENE; BARD1 GENE; CANCER GRADING; CHEK2 GENE; DNA DAMAGE; DNA REPAIR; FEMALE; GENETIC DISORDER; GENETIC SCREENING; GERMLINE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NBN GENE; PALB2 GENE; RAD51D GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT ANALYSIS; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; POLAND; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; DNA DAMAGE; DNA REPAIR; FEMALE; GENETIC TESTING; GERM-LINE MUTATION; HOMOLOGOUS RECOMBINATION; HUMANS; MIDDLE AGED; NEOPLASM GRADING; POLAND; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84939157137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130393     Document Type: Article

References (61)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-1948. doi:10.1056/NEJMra1001389 PMID: 21067385.
2. Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, et al. The negative effect of triplenegative breast cancer on outcome after breast-conserving therapy. Ann Surg Oncol. 2011; 18: 2858-2865. doi:10.1245/s10434-011-1669-4 PMID: 21442346.
3. Domagala P, Huzarski T, Lubinski J, Gugala K, DomagalaW. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch. 2011; 458: 55-64doi:10.1007/s00428-010-0988-3 PMID: 20941507.
4. Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: Implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014; 145: 707-714. doi:10.1007/s10549-014-2980-0 PMID: 24807107.
5. Yiannakopoulou E. Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: Clinical implications. Cell Oncol (Dordr). 2014; 37: 1-8.
6. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009; 461: 1071-1078. doi:10.1038/nature08467 PMID: 19847258.
7. Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited. Biochim Biophys Acta. 2014; 1846: 201-215. doi:10.1016/j.bbcan.2014.07.004 PMID: 25026313.
8. Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol. 2010; 17: 1247-1254. doi:10.1038/nsmb.1915 PMID: 20871615.
9. Yamamoto Y, Miyamoto M, Tatsuda D, Kubo M, Nakagama H, Nakamura Y, et al. A rare polymorphic variant of NBS1 reduces DNA repair activity and elevates chromosomal instability. Cancer Res. 2014; 74: 3707-3715. doi:10.1158/0008-5472.CAN-13-3037 PMID: 24830725.
10. Narod SA. Testing for CHEK2 in the cancer genetics clinic: Ready for prime time? Clin Genet. 2010; 78: 1-7. doi:10.1111/j.1399-0004.2010.01583.x PMID: 21175597.
11. Alvarez-Quilon A, Serrano-Benitez A, Lieberman JA, Quintero C, Sanchez-Gutierrez D, Escudero LM, et al. ATM specifically mediates repair of double-strand breaks with blocked DNA ends. Nat Commun. 2014; 5: 3347. doi:10.1038/ncomms4347 PMID: 24572510.
12. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, Livingston DM. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev. 2006; 20: 34-46. PMID: 16391231.
13. Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, et al. A Finnish founder mutation in RAD51D: Analysis in breast, ovarian, prostate, and colorectal cancer. J Med Genet. 2012; 49: 429-432. doi:10.1136/jmedgenet-2012-100852 PMID: 22652533.
14. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66: 8109-8115. PMID: 16912188.
15. Domagala P, Wokolorczyk D, Cybulski C, Huzarski T, Lubinski J, Domagala W. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012; 132: 937-945. doi:10.1007/s10549-011-1635-7 PMID: 21701879.
16. Gronwald J, Byrski T, Huzarski T, Oszurek O, Janicka A, Szymanska-Pasternak J, et al. Hereditary breast and ovarian cancer. Hered Cancer Clin Pract. 2008; 6: 88-98. doi:10.1186/1897-4287-6-2-88 PMID: 19804604.
17. Szwiec M, Jakubowska A, Gorski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: An update. Clin Genet. 2015; 87: 288-92. doi:10.1111/cge.12360 PMID: 24528374.
18. Gorski B, Debniak T, Masojc B, Mierzejewski M, Medrek K, Cybulski C, et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer. 2003; 106: 379-381. PMID: 12845677.
19. Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet. 2010; 11: 20. doi:10.1186/1471-2350-11-20PMID: 20122277.
20. Bogdanova N, Cybulski C, Bermisheva M, Datsyuk I, Yamini P, Hillemanns P, et al. A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer. Breast Cancer Res Treat. 2009; 118: 207-211. doi:10.1007/s10549-008-0189-9 PMID: 18807267.
21. Roznowski K, Januszkiewicz-Lewandowska D, Mosor M, Pernak M, Litwiniuk M, Nowak J. I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer. Breast Cancer Res Treat. 2008; 110: 343-348. PMID: 17899368.
22. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004; 75: 1131-1135. PMID: 15492928.
23. Cybulski C, Wokolorczyk D, Huzarski T, Byrski T, Gronwald J, Gorski B, et al. A deletion in CHEK2 of 5, 395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat. 2007; 102: 119-122. PMID: 16897426.
24. Lubinski J, Korzen M, Gorski B, Cybulski C, Debniak T, Jakubowska A, et al. Genetic contribution to all cancers: The first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. Breast Cancer Res Treat. 2009; 114: 121-126. doi:10.1007/s10549-008-9974-8 PMID: 18415014.
25. Han FF, Guo CL, Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility: Evidence from a meta-analysis. DNA Cell Biol. 2013; 32: 329-335. doi:10.1089/dna.2013.1970 PMID: 23713947.
26. Gao P, Ma N, Li M, Tian QB, Liu DW. Functional variants in NBS1 and cancer risk: Evidence from a meta-analysis of 60 publications with 111 individual studies. Mutagenesis. 2013; 28: 683-697. doi:10.1093/mutage/get048 PMID: 24113799.
27. Roeb W, Higgins J, King MC. Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Hum Mol Genet. 2012; 21: 2738-2744. doi:10.1093/hmg/dds101 PMID: 22419737.
28. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007; 446: 316-319. PMID: 17287723.
29. Ratajska M, Antoszewska E, Piskorz A, Brozek I, Borg A, Kusmierek H, et al. Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat. 2012; 131: 89-97. doi:10.1007/s10549-011-1403-8 PMID: 21344236.
30. Wang X, Weaver DT. The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res. 2011; 1: 301-327. PMID: 21968427.
31. Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008; 26: 3785-3790. doi:10.1200/JCO.2008.16.0812 PMID: 18591545.
32. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999; 4: 511-518. PMID: 10549283.
33. Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014; 147: 401-405. doi:10.1007/s10549-014-3100-x PMID: 25129345.
34. Tun NM, Villani G, Ong K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triplenegative breast cancer: A meta-analysis. Clin Genet. 2014; 85: 43-48. doi:10.1111/cge.12270 PMID: 24000781.
35. Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012; 118: 2787-2795. doi:10.1002/cncr.26576PMID:22614657.
36. Pern F, Bogdanova N, Schurmann P, Lin M, Ay A, Langer F, et al. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of german patients with triple-negative breast cancer. PLoS One. 2012; 7: E47993. doi:10.1371/journal.pone.0047993 PMID: 23110154.
37. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011; 17: 1082-1089. doi:10.1158/1078-0432.CCR-10-2560 PMID: 21233401.
38. Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer. 2004; 110: 683-686. PMID: 15146557.
39. Perkowska M, BroZek I, Wysocka B, Haraldsson K, Sandberg T, Johansson U, et al. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from Northeastern Poland. Hum Mutat. 2003; 21: 553-554. PMID: 12673802.
40. Lubinski J, Korzen M, Gorski B, Cybulski C, Debniak T, Jakubowska A, et al. Breast cancer susceptibility genes. J BUON. 2007; 12 Suppl 1: S23-9. PMID: 17935274.
41. Janavicius R. Founder BRCA1/2 mutations in the Europe: Implications for hereditary breastovarian cancer prevention and control. EPMA J. 2010; 1: 397-412. doi:10.1007/s13167-010-0037-y PMID: 23199084.
42. Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, et al. Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet. 2011; 52: 325-330. doi:10.1007/s13353-011-0040-6 PMID: 21503673.
43. Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, et al. Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res. 2008; 644: 64-70. doi:10.1016/j.mrfmmm.2008.07.005 PMID: 18694767.
44. Sweet K, Senter L, Pilarski R, Wei L, Toland AE. Characterization of BRCA1 ring finger variants of uncertain significance. Breast Cancer Res Treat. 2010; 119: 737-743. doi:10.1007/s10549-009-0438-6PMID: 19543972.
45. Ransburgh DJ, Chiba N, Ishioka C, Toland AE, Parvin JD. Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Res. 2010; 70: 988-995. doi: 10.1158/0008-5472.CAN-09-2850 PMID: 20103620.
46. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, et al. BRCA2 mutationassociated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007; 31: 121-128. PMID: 17197928.
47. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014; 20: 764-775. doi10.1158/1078-0432.CCR-13-2287 PMID: 24240112.
48. Cybulski C, Gorski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojc B, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res. 2004; 64: 1215-1219. PMID: 14973119.
49. Steffen J, Nowakowska D, Niwinska A, Czapczak D, Kluska A, Piatkowska M, et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer. 2006; 119: 472-475. PMID: 16770759.
50. Teodorczyk U, Cybulski C, Wokolorczyk D, Jakubowska A, Starzynska T, Lawniczak M, et al. The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer. 2013; 12: 473-478. doi:10.1007/s10689-012-9599-2 PMID: 23296741.
51. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, et al. Analysis of PALB2/FANCNassociated breast cancer families. Proc Natl Acad Sci U S A. 2007; 104: 6788-6793. PMID: 17420451.
52. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in nijmegen breakage syndrome. Cell. 1998; 93: 467-476. PMID: 9590180.
53. Krenzlin H, Demuth I, Salewsky B, Wessendorf P, Weidele K, Burkle A, et al. DNA damage in nijmegen breakage syndrome cells leads to PARP hyperactivation and increased oxidative stress. PLoS Genet. 2012; 8: E1002557. doi:10.1371/journal.pgen.1002557 PMID: 22396666.
54. Keimling M, Volcic M, Csernok A, Wieland B, Dork T, Wiesmuller L. Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways. FASEB J. 2011; 25: 3849-3860doi:10.1096/fj.11-185546PMID: 21778326.
55. Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, Bebb DG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther. 2010; 9: 347-357. doi:10.1158/1535-7163.MCT-09-0872 PMID: 20124459.
56. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol. 2004; 24: 708-718. PMID: 14701743.
57. Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: Regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res. 2011; 17: 401-405. doi:10.1158/1078-0432.CCR-10-1215 PMID: 21088254.
58. Pfeifer W, Sokolenko AP, Potapova ON, Bessonov AA, Ivantsov AO, Laptiev SA, et al. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. Breast Cancer Res Treat. 2014; 148: 675-683. doi:10.1007/s10549-014-3206-1 PMID: 25414026.
59. Tavtigian SV, Chenevix-Trench G. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Biomark Med. 2014; 8: 589-603. doi:10.2217/bmm.13.143 PMID: 24796624.
60. Schroder-Heurich B, Bogdanova N, Wieland B, Xie X, Noskowicz M, Park-Simon TW, et al. Functional deficiency of NBN, the nijmegen breakage syndrome protein, in a p.R215W mutant breast cancer cell line. BMC Cancer. 2014; 14: 434. doi:10.1186/1471-2407-14-434 PMID: 24928521.
61. Poumpouridou N, Kroupis C. Hereditary breast cancer: Beyond BRCA genetic analysis; PALB2 emerges. Clin Chem Lab Med. 2011; 50: 423-434. doi:10.1515/cclm-2011-0840 PMID: 22505525.